Table 1 Clinicobiological characteristics of BRAFV600E-mutated NSCLC patients.
Patient | Age at baseline (y/o) | Gender | Smoking status | Line of therapy | Best response | Number of metastatic sites at baseline | PD sites | Duration of treatment (months) | Progression-free survival (months) | Overall survival (months) | ECOG PS at time of CTC Isolation | Time between CTC - therapy initiation (months) | Detected CTCs by CellSearch at PD (/7.5 mL) | Isolated CTCs by FACS at PD (/30 mL) | Biopsy at PD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P1 | 65 | F | Non-smoker | 2nd | PR | ≤2 | Lung | 46.8 | 44.8 | 72.4 | 1 | 46.8 | 0 | 25 | Yes |
P2 | 69 | F | Smoker | 2nd | PR | ≤2 | Adrenal | 16.9 | 14.2 | 37.4 | 1 | 16.9 | 14 | 16 | Yes |
P3 | 58 | M | Smoker | 1st | SD | ≤2 | Bone peritoneal nodal | 13.3 | 10.3 | 11.5 | 2 | 13.3 | NA | 23 | Yes |
P4 | 62 | M | Smoker | 2nd | PR | ≤2 | Bone | 30.2 | 27.0 | 58.3 | 1 | 49.6 | 0* | 17* | No |
P5 | 68 | M | Smoker | 2nd | PR | >2 | Liver brain | 7.5 | 6.9 | 26.3 | 2 | 7.6 | 0 | 8 | No |
P6 | 81 | F | Non-smoker | 1st | SD | ≤2 | Liver bone | 16.4 | 16.1 | 18.5 | 2 | 24.3 | 3* | 28* | Yes |
P7 | 69 | M | Non-smoker | 2nd | PR | ≤2 | Liver (oligoPD) | Ongoing | 31.9 | 73.7 | 1 (0)** | 60.9 (65.8)** | 0 (0)** | 22 (11)** | Yes*** |
